Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field
CRISPR/Cas9. TALEN. Zinc finger nuclease tech. The ARC nuclease.
You may have heard about those first 3 gene-editing platforms. But what’s an ARC nuclease? …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
